The indirect controlling shareholders of Huashen Technology (000790.SZ) increased their total shares by 1%
According to the Zhitong Finance App, Huashen Technology (000790.SZ) issued an announcement. As of the disclosure date of this announcement, the implementation period of this increase plan has passed. Chengdu Yuanhong Biotechnology Co., Ltd., the indirect controlling shareholder of the company, has increased its holdings of the company's shares by 6,280,000 shares through centralized bidding transactions through the Shenzhen Stock Exchange trading system, accounting for 1% of the current total share capital of the company, and the total amount paid is about 197636 million yuan. The current plan to increase its holdings has not yet been completed, and Chengdu Yuanhong will continue to increase its holdings in accordance with the holdings increase plan.
Lansheng Co., Ltd. (600826.SH) completed the repurchase of 2.15% of the shares at a cost of 100 million yuan
Lan Sheng Co., Ltd. (600826.SH) announced that as of May 6, 2024, the company's current share repurchase plan is actually...
RheinBio (002166.SZ): 1.08% of shares have been cumulatively repurchased
Gelonghui, May 6, 丨 Rhine Biotech (002166.SZ) announced that as of April 30, 2024, the total number of shares repurchased by the company through centralized bidding transactions through the stock repurchase special securities account was 7,992,071 shares, accounting for 1.08% of the company's total share capital. The maximum transaction price was 7.00 yuan/share, the minimum transaction price was 5.90 yuan/share, and the total transaction amount was RMB 49,9551 (excluding transaction fees).
Zhendong Pharmaceutical (300158.SZ) has repurchased 2.16% of its shares at a total cost of 103 million yuan
Zhitong Finance App News, Zhendong Pharmaceutical (300158.SZ) announced that the company's repurchase has been completed. As of April 30, 2024, the company had repurchased a total of 22.174,900 shares of the company's shares, accounting for 2.16% of the company's total share capital, and the total transaction amount was 103 million yuan (excluding transaction fees).
Fosun Pharmaceutical (02196.HK) has yet to repurchase shares
Gelonghui, May 6, 丨 Fosun Pharmaceutical (02196.HK) issued an announcement. From March 26, 2024 (that is, the date the board of directors reviewed and approved the repurchase plan) to April 30, 2024, the company has not yet repurchased shares under the repurchase plan.
China Grants Marketing Authorization to Sunflower Pharma's Electrolyte Powder for Constipation
China's medical products administrator granted marketing authorization to Sunflower Pharmaceutical (SHE:002737) subsidiary Harbin Sunflower Pharmaceutical's compound polyethylene glycol electrolyte po